Modiblast holds patents issued in both Europe and the U.S. covering the use of various combinations of immunomodulators (kits) for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These kits can be administered by any route and at a wide range of doses. The countries in which we have validated patents account for more than 75% of the global leukemia market.